Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CHRISTIE BALLANTYNE and SALIM VIRANI.
CHRISTIE BALLANTYNE
Connection Strength
30.311
SALIM VIRANI
  1. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. J Clin Lipidol. 2023 Mar-Apr; 17(2):208-218.
    View in: PubMed
    Score: 0.828
  2. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology. Am J Prev Cardiol. 2023 Mar; 13:100472.
    View in: PubMed
    Score: 0.828
  3. Has the 'strength' of fish oil therapy been 'reduced'? Reconciling the results of REDUCE-IT and STRENGTH. Eur Heart J Cardiovasc Pharmacother. 2021 05 23; 7(3):e7-e8.
    View in: PubMed
    Score: 0.733
  4. Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB? Eur Heart J. 2020 10 21; 41(40):3910-3912.
    View in: PubMed
    Score: 0.704
  5. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
    View in: PubMed
    Score: 0.623
  6. Low-Density Lipoprotein Cholesterol: Is 160 the New 190? Circulation. 2018 11 20; 138(21):2326-2329.
    View in: PubMed
    Score: 0.616
  7. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
    View in: PubMed
    Score: 0.593
  8. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
    View in: PubMed
    Score: 0.553
  9. From Plaque Burden to Plaque Composition: Toward?Personalized Risk?Assessment. JACC Cardiovasc Imaging. 2017 03; 10(3):250-252.
    View in: PubMed
    Score: 0.547
  10. Provider understanding of the 2013 ACC/AHA cholesterol guideline. J Clin Lipidol. 2016 May-Jun; 10(3):497-504.e4.
    View in: PubMed
    Score: 0.500
  11. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
    View in: PubMed
    Score: 0.485
  12. Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis. Am J Cardiol. 2013 Nov 01; 112(9):1287-92.
    View in: PubMed
    Score: 0.426
  13. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis. 2012 Jun; 222(2):551-6.
    View in: PubMed
    Score: 0.389
  14. Chromosome 9p21 single nucleotide polymorphisms are not associated with recurrent myocardial infarction in patients with established coronary artery disease. Circ J. 2012; 76(4):950-6.
    View in: PubMed
    Score: 0.385
  15. Update on therapies targeting HDL: the mystery continues. Curr Opin Lipidol. 2011 Dec; 22(6):514-6.
    View in: PubMed
    Score: 0.380
  16. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012 Jan 17; 125(2):241-9.
    View in: PubMed
    Score: 0.380
  17. Barriers to non-HDL cholesterol goal attainment by providers. Am J Med. 2011 Sep; 124(9):876-80.e2.
    View in: PubMed
    Score: 0.373
  18. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis. 2011 Dec; 219(2):596-602.
    View in: PubMed
    Score: 0.372
  19. Usefulness of single nucleotide polymorphism in chromosome 4q25 to predict in-hospital and long-term development of atrial fibrillation and survival in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2011 May 15; 107(10):1504-9.
    View in: PubMed
    Score: 0.362
  20. Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. Eur Heart J. 2011 Feb; 32(4):459-68.
    View in: PubMed
    Score: 0.351
  21. Preoperative statin therapy decreases risk of postoperative renal insufficiency. Cardiovasc Ther. 2010 Apr; 28(2):80-6.
    View in: PubMed
    Score: 0.339
  22. Obesity: an independent predictor of in-hospital postoperative renal insufficiency among patients undergoing cardiac surgery? Tex Heart Inst J. 2009; 36(6):540-5.
    View in: PubMed
    Score: 0.310
  23. Does preoperative statin therapy improve outcomes in patients undergoing isolated cardiac valve surgery? Am J Cardiol. 2008 Nov 01; 102(9):1235-9.
    View in: PubMed
    Score: 0.303
  24. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J. 2008 Mar; 155(3):541-6.
    View in: PubMed
    Score: 0.289
  25. How to identify patients with vulnerable plaques. Diabetes Obes Metab. 2008 Sep; 10(10):824-33.
    View in: PubMed
    Score: 0.286
  26. Racial and ethnic disparities in cardiovascular disease - analysis across major US national databases. J Natl Med Assoc. 2024 Jun; 116(3):258-270.
    View in: PubMed
    Score: 0.221
  27. Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999-2020. JAMA Cardiol. 2023 12 01; 8(12):1185-1187.
    View in: PubMed
    Score: 0.218
  28. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2023 11 09; 30(16):1731-1740.
    View in: PubMed
    Score: 0.217
  29. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.
    View in: PubMed
    Score: 0.210
  30. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease. Circulation. 2023 05 02; 147(18):1411-1413.
    View in: PubMed
    Score: 0.207
  31. Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine-Brief Report. Arterioscler Thromb Vasc Biol. 2022 12; 42(12):1461-1467.
    View in: PubMed
    Score: 0.203
  32. Statin Use and Risk of Diabetes by Subclinical Atherosclerosis Burden (from a Multi-Ethnic Study of Atherosclerosis Report). Am J Cardiol. 2022 12 01; 184:7-13.
    View in: PubMed
    Score: 0.201
  33. Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: The multi-ethnic study of atherosclerosis. Prog Cardiovasc Dis. 2022 Sep-Oct; 74:19-27.
    View in: PubMed
    Score: 0.199
  34. PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Vasc Health Risk Manag. 2022; 18:555-566.
    View in: PubMed
    Score: 0.199
  35. Guideline-Concordant Statin Therapy Use?in Secondary Prevention: Should the Medical Community Wait for Divine Intervention? J Am Coll Cardiol. 2022 05 10; 79(18):1814-1817.
    View in: PubMed
    Score: 0.196
  36. Lipoprotein(a) and ethnicities. Atherosclerosis. 2022 05; 349:42-52.
    View in: PubMed
    Score: 0.196
  37. Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2022 06; 350:82-89.
    View in: PubMed
    Score: 0.195
  38. Association of participation in Cardiac Rehabilitation with Social Vulnerability Index: The behavioral risk factor surveillance system. Prog Cardiovasc Dis. 2022 Mar-Apr; 71:86-91.
    View in: PubMed
    Score: 0.193
  39. Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. Circulation. 2022 01 25; 145(4):259-267.
    View in: PubMed
    Score: 0.190
  40. Leveraging structured and unstructured electronic health record data to detect reasons for suboptimal statin therapy use in patients with atherosclerotic cardiovascular disease. Am J Prev Cardiol. 2022 Mar; 9:100300.
    View in: PubMed
    Score: 0.190
  41. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
    View in: PubMed
    Score: 0.188
  42. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 08 31; 78(9):960-993.
    View in: PubMed
    Score: 0.186
  43. Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures? Curr Cardiol Rep. 2021 07 16; 23(9):116.
    View in: PubMed
    Score: 0.185
  44. Prevalence and Determinants of Difficulty in Accessing Medical Care in U.S. Adults. Am J Prev Med. 2021 10; 61(4):492-500.
    View in: PubMed
    Score: 0.185
  45. Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 07 01; 6(7):782-790.
    View in: PubMed
    Score: 0.185
  46. Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. Popul Health Manag. 2022 02; 25(1):39-45.
    View in: PubMed
    Score: 0.184
  47. Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2021 08; 35(4):793-800.
    View in: PubMed
    Score: 0.183
  48. Health care costs associated with primary care physicians versus nurse practitioners and physician assistants. J Am Assoc Nurse Pract. 2021 05 31; 33(11):967-974.
    View in: PubMed
    Score: 0.183
  49. Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease. Am J Med. 2021 08; 134(8):1047-1051.e2.
    View in: PubMed
    Score: 0.181
  50. Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond. Curr Opin Endocrinol Diabetes Obes. 2021 04 01; 28(2):114-121.
    View in: PubMed
    Score: 0.181
  51. Recreational substance use among patients with premature atherosclerotic cardiovascular disease. Heart. 2021 04; 107(8):650-656.
    View in: PubMed
    Score: 0.180
  52. Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affair Healthcare System. Cardiovasc Drugs Ther. 2022 04; 36(2):295-300.
    View in: PubMed
    Score: 0.179
  53. Racial and geographic disparities in influenza vaccination in the U.S. among individuals with atherosclerotic cardiovascular disease: Renewed importance in the setting of COVID-19. Am J Prev Cardiol. 2021 Mar; 5:100150.
    View in: PubMed
    Score: 0.179
  54. Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther. 2022 02; 36(1):93-102.
    View in: PubMed
    Score: 0.178
  55. E-cigarette Use and Risk Behaviors among Lesbian, Gay, Bisexual, and Transgender Adults: The Behavioral Risk Factor Surveillance System (BRFSS) Survey. Kans J Med. 2020; 13:318-321.
    View in: PubMed
    Score: 0.178
  56. Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women. J Clin Endocrinol Metab. 2020 12 01; 105(12).
    View in: PubMed
    Score: 0.177
  57. Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. J Am Heart Assoc. 2020 11 17; 9(22):e017915.
    View in: PubMed
    Score: 0.177
  58. Racial and Geographic Disparities in Internet Use in the U.S. Among Patients With Hypertension or Diabetes: Implications for Telehealth in the Era of COVID-19. Diabetes Care. 2021 01; 44(1):e15-e17.
    View in: PubMed
    Score: 0.176
  59. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective. Cardiovasc Drugs Ther. 2021 12; 35(6):1269-1279.
    View in: PubMed
    Score: 0.175
  60. Non-traditional risk factors and the risk of myocardial infarction in the young in the US population-based cohort. Int J Cardiol Heart Vasc. 2020 Oct; 30:100634.
    View in: PubMed
    Score: 0.175
  61. Letter to the Editor: Temporal Trends in E-Cigarette and Cigarette Use Among US Adults by US State: Behavioral Risk Factor Surveillance System, 2016 to 2018. Popul Health Manag. 2021 06; 24(3):414-415.
    View in: PubMed
    Score: 0.175
  62. Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
    View in: PubMed
    Score: 0.174
  63. Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD. Cardiovasc Drugs Ther. 2020 12; 34(6):745-754.
    View in: PubMed
    Score: 0.174
  64. Coronary artery disease in the young in the US population-based cohort. Am J Cardiovasc Dis. 2020; 10(3):189-194.
    View in: PubMed
    Score: 0.174
  65. Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2020 08 03; 3(8):e2011051.
    View in: PubMed
    Score: 0.173
  66. Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry. Am J Med. 2020 12; 133(12):1424-1432.e1.
    View in: PubMed
    Score: 0.172
  67. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Curr Atheroscler Rep. 2020 06 03; 22(7):25.
    View in: PubMed
    Score: 0.171
  68. Temporal Trends in E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016 to 2018. Am J Med. 2020 09; 133(9):e508-e511.
    View in: PubMed
    Score: 0.169
  69. Facility-Level Variation in Cardiac Stress Test Use Among Patients With Diabetes: Findings From the Veterans Affairs National Database. Diabetes Care. 2020 05; 43(5):e58-e60.
    View in: PubMed
    Score: 0.169
  70. The Use of Sex-Specific Factors in the Assessment of Women's Cardiovascular Risk. Circulation. 2020 02 18; 141(7):592-599.
    View in: PubMed
    Score: 0.168
  71. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.166
  72. "Zero": The New Superhero or Superhero in Training? J Am Coll Cardiol. 2019 11 05; 74(18):2331.
    View in: PubMed
    Score: 0.165
  73. The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. J Clin Lipidol. 2019 Sep - Oct; 13(5):797-803.e1.
    View in: PubMed
    Score: 0.162
  74. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
    View in: PubMed
    Score: 0.162
  75. The Use of Risk Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-society Cholesterol Guidelines. Curr Cardiovasc Risk Rep. 2019; 13(7).
    View in: PubMed
    Score: 0.159
  76. Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. Am J Med. 2019 09; 132(9):e693-e700.
    View in: PubMed
    Score: 0.159
  77. Facility-Level Variation in Stress Test Utilization in Veterans With Ischemic Heart Disease. JACC Cardiovasc Imaging. 2019 07; 12(7 Pt 1):1292-1293.
    View in: PubMed
    Score: 0.158
  78. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
    View in: PubMed
    Score: 0.157
  79. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
    View in: PubMed
    Score: 0.155
  80. Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol. 2018 12 07; 13(12):1842-1850.
    View in: PubMed
    Score: 0.154
  81. Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA. 2018 Jul; 31(7):39-45.
    View in: PubMed
    Score: 0.150
  82. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018 06; 23(3):232-240.
    View in: PubMed
    Score: 0.147
  83. Short-Term Global Cardiovascular Disease Risk?Prediction in Older Adults. J Am Coll Cardiol. 2018 06 05; 71(22):2527-2536.
    View in: PubMed
    Score: 0.147
  84. Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2017 Dec 15; 6(12).
    View in: PubMed
    Score: 0.144
  85. Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. Popul Health Manag. 2018 06; 21(3):209-216.
    View in: PubMed
    Score: 0.143
  86. The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Atherosclerosis. 2017 07; 262:131-137.
    View in: PubMed
    Score: 0.139
  87. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiol. 2017 04 01; 2(4):361-369.
    View in: PubMed
    Score: 0.137
  88. Practice-Level Variation in?Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. J Am Coll Cardiol. 2016 09 20; 68(12):1368-9.
    View in: PubMed
    Score: 0.133
  89. Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. Am Heart J. 2016 Nov; 181:74-82.
    View in: PubMed
    Score: 0.132
  90. Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. Am J Cardiol. 2016 Oct 15; 118(8):1144-1149.
    View in: PubMed
    Score: 0.131
  91. Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. Clin Cardiol. 2016 Apr; 39(4):185-91.
    View in: PubMed
    Score: 0.128
  92. A dataset to assess providers? knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Data Brief. 2016 Jun; 7:595-8.
    View in: PubMed
    Score: 0.128
  93. Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Atherosclerosis. 2016 Mar; 246:115-20.
    View in: PubMed
    Score: 0.126
  94. Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry. J Am Coll Cardiol. 2015 Oct 20; 66(16):1803-1812.
    View in: PubMed
    Score: 0.124
  95. The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia. Curr Atheroscler Rep. 2015 May; 17(5):508.
    View in: PubMed
    Score: 0.120
  96. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol. 2015 Jan 20; 65(2):111-21.
    View in: PubMed
    Score: 0.118
  97. Reply: Frequency of inappropriate and nonrecommended prasugrel prescription: great variations. J Am Coll Cardiol. 2014 Dec 09; 64(22):2434-5.
    View in: PubMed
    Score: 0.117
  98. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014 Nov; 37(11):653-9.
    View in: PubMed
    Score: 0.116
  99. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol. 2015 Jan 01; 115(1):21-6.
    View in: PubMed
    Score: 0.116
  100. Association of body mass index and waist circumference with subclinical atherosclerosis in retired NFL players. South Med J. 2014 Oct; 107(10):633-9.
    View in: PubMed
    Score: 0.116
  101. Relation between playing position and coronary artery calcium scores in retired National Football League players. Am J Cardiol. 2014 Dec 15; 114(12):1836-40.
    View in: PubMed
    Score: 0.116
  102. Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014 Oct; 236(2):251-6.
    View in: PubMed
    Score: 0.114
  103. Frequency and practice-level variation in inappropriate and nonrecommended prasugrel prescribing: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014 Jul 01; 63(25 Pt A):2876-7.
    View in: PubMed
    Score: 0.112
  104. Neck circumference is not associated with subclinical atherosclerosis in retired National Football League players. Clin Cardiol. 2014 Jul; 37(7):402-7.
    View in: PubMed
    Score: 0.111
  105. Decrease the incentives to order lipid panels--reply. JAMA Intern Med. 2014 Mar; 174(3):473-4.
    View in: PubMed
    Score: 0.111
  106. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1069-77.
    View in: PubMed
    Score: 0.111
  107. Association between preoperative diuretic use and in-hospital outcomes after cardiac surgery. Cardiovasc Ther. 2013 Oct; 31(5):291-7.
    View in: PubMed
    Score: 0.108
  108. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study. Clin Chem. 2013 Dec; 59(12):1802-10.
    View in: PubMed
    Score: 0.108
  109. Correlates of repeat lipid testing in patients with coronary heart disease. JAMA Intern Med. 2013 Aug 12; 173(15):1439-44.
    View in: PubMed
    Score: 0.107
  110. Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study. Circ Heart Fail. 2013 Sep 01; 6(5):936-43.
    View in: PubMed
    Score: 0.106
  111. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke. 2013 Jul; 44(7):1803-8.
    View in: PubMed
    Score: 0.105
  112. Comparison by meta-analysis of mortality after isolated coronary artery bypass grafting in women versus men. Am J Cardiol. 2013 Aug 01; 112(3):309-17.
    View in: PubMed
    Score: 0.105
  113. Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. J Lipid Res. 2013 Jul; 54(7):1980-7.
    View in: PubMed
    Score: 0.105
  114. Association between statins and infections after coronary artery bypass grafting. Int J Cardiol. 2013 Sep 20; 168(1):117-20.
    View in: PubMed
    Score: 0.101
  115. Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012 Nov-Dec; 6(6):545-52.
    View in: PubMed
    Score: 0.098
  116. The 9p21 genetic variant is additive to carotid intima media thickness and plaque in improving coronary heart disease risk prediction in white participants of the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2012 May; 222(1):135-7.
    View in: PubMed
    Score: 0.096
  117. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res. 2012 Mar; 53(3):556-560.
    View in: PubMed
    Score: 0.096
  118. Association of gender with morbidity and mortality after isolated coronary artery bypass grafting. A propensity score matched analysis. Int J Cardiol. 2013 Jul 15; 167(1):180-4.
    View in: PubMed
    Score: 0.096
  119. Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training. J Clin Lipidol. 2012 Jan-Feb; 6(1):50-7.
    View in: PubMed
    Score: 0.095
  120. Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. Am Heart J. 2011 Oct; 162(4):725-732.e1.
    View in: PubMed
    Score: 0.093
  121. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 2011 Dec; 219(2):737-42.
    View in: PubMed
    Score: 0.093
  122. Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. Am Heart J. 2011 Jun; 161(6):1140-6.
    View in: PubMed
    Score: 0.091
  123. Isolated coronary artery bypass grafting in obese individuals: a propensity matched analysis of outcomes. Circ J. 2011; 75(6):1378-85.
    View in: PubMed
    Score: 0.091
  124. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011 Apr 05; 123(13):1367-76.
    View in: PubMed
    Score: 0.091
  125. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009 Dec 15; 54(25):2388-95.
    View in: PubMed
    Score: 0.083
  126. Heart Failure and Death in Older Adults With Elevated Cardiac Biomarkers But Without Risk Factors: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2025 Aug 19; 14(16):e042140.
    View in: PubMed
    Score: 0.061
  127. From Trials to Practice: Implementing a Clinical Intervention in Community Settings. J Prim Care Community Health. 2025 Jan-Dec; 16:21501319251339190.
    View in: PubMed
    Score: 0.060
  128. Early-onset atherosclerotic cardiovascular disease. Eur J Prev Cardiol. 2025 Jan 27; 32(2):100-112.
    View in: PubMed
    Score: 0.059
  129. Trends in Cardiovascular Disease-Related Mortality in Texas. Tex Heart Inst J. 2024 Jul-Dec; 51(2):e248426.
    View in: PubMed
    Score: 0.059
  130. Vital Exhaustion and Biomarkers Associated With Cardiovascular Risk: The ARIC Study. JACC Adv. 2024 Nov; 3(11):101355.
    View in: PubMed
    Score: 0.058
  131. Predictors of incident stroke among individuals without coronary artery calcification: A pooled cohort analysis from the Multi-Ethnic Study of Atherosclerosis, Jackson Heart Study, and Framingham Heart Study. Vasc Med. 2024 12; 29(6):632-639.
    View in: PubMed
    Score: 0.058
  132. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024 Sep-Oct; 18(5):e647-e663.
    View in: PubMed
    Score: 0.058
  133. Comparing Cardiovascular Risk Classification of U.S. Adults According to Pooled Cohort Equations and PREVENT Equations: Cross-Sectional Analysis of the National Health and Nutrition Examination Survey. Ann Intern Med. 2024 Oct; 177(10):1444-1448.
    View in: PubMed
    Score: 0.058
  134. Global burden of cardiovascular disease attributable to smoking, 1990-2019: an analysis of the 2019 Global Burden of Disease Study. Eur J Prev Cardiol. 2024 Jul 23; 31(9):1123-1131.
    View in: PubMed
    Score: 0.057
  135. Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study. Circulation. 2024 Jul 16; 150(3):250-252.
    View in: PubMed
    Score: 0.057
  136. Association of High-Density Lipoprotein Parameters and Risk of Heart?Failure: A Multicohort Analysis. JACC Heart Fail. 2024 Jul; 12(7):1242-1253.
    View in: PubMed
    Score: 0.056
  137. Statin utilization and cardiovascular outcomes in a real-world primary prevention cohort of older adults. Am J Prev Cardiol. 2024 Jun; 18:100664.
    View in: PubMed
    Score: 0.056
  138. Trends in sleep apnea and heart failure related mortality in the United States from 1999 to 2019. Curr Probl Cardiol. 2024 Feb; 49(2):102342.
    View in: PubMed
    Score: 0.055
  139. County-Level Cardiologist Density and Mortality in the United States. J Am Heart Assoc. 2023 12 05; 12(23):e031686.
    View in: PubMed
    Score: 0.055
  140. Novel Size-Based High-Density Lipoprotein Subspecies and Incident Vascular Events. J Am Heart Assoc. 2023 11 07; 12(21):e031160.
    View in: PubMed
    Score: 0.054
  141. Association Between Cardiologist Density and Mortality in Urban and Rural Counties in the United States. Am J Cardiol. 2024 01 01; 210:279-282.
    View in: PubMed
    Score: 0.054
  142. Implementation and Evaluation of a mHealth-Based Community Health Worker Feedback Loop for Hispanics with and at Risk for Diabetes. J Gen Intern Med. 2024 Feb; 39(2):229-238.
    View in: PubMed
    Score: 0.054
  143. Age-Related Differences in the Contribution of Systolic Blood Pressure and Biomarkers to Cardiovascular Disease Risk Prediction: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Cardiol. 2023 10 01; 204:295-301.
    View in: PubMed
    Score: 0.053
  144. Association of Long-term Change in N-Terminal Pro-B-Type Natriuretic Peptide With Incident Heart Failure and Death. JAMA Cardiol. 2023 03 01; 8(3):222-230.
    View in: PubMed
    Score: 0.052
  145. Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers: The ARIC Study. JACC Heart Fail. 2023 04; 11(4):440-450.
    View in: PubMed
    Score: 0.052
  146. Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2022 11; 11(21):e026762.
    View in: PubMed
    Score: 0.051
  147. Comparison of Longitudinal Skeletal Thigh Muscle Findings With Magnetic Resonance Imaging in Patients With Peripheral Artery Disease With-Versus-Without Diabetes Mellitus. Am J Cardiol. 2022 Oct 15; 181:130-138.
    View in: PubMed
    Score: 0.050
  148. Long-Term Effectiveness of the TIME Intervention to Improve Diabetes Outcomes in Low-Income Settings: a 2-Year Follow-Up. J Gen Intern Med. 2022 09; 37(12):3062-3069.
    View in: PubMed
    Score: 0.048
  149. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
    View in: PubMed
    Score: 0.048
  150. Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. Am J Med. 2022 05; 135(5):603-606.
    View in: PubMed
    Score: 0.047
  151. Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circ Cardiovasc Qual Outcomes. 2021 09; 14(9):e007485.
    View in: PubMed
    Score: 0.047
  152. Association between circulating Galectin-3 and arterial stiffness in older adults. Vasa. 2021 Nov; 50(6):439-445.
    View in: PubMed
    Score: 0.046
  153. Mentored implementation to initiate a diabetes program in an underserved community: a pilot study. BMJ Open Diabetes Res Care. 2021 08; 9(1).
    View in: PubMed
    Score: 0.046
  154. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). J Clin Lipidol. 2021 Sep-Oct; 15(5):649-652.
    View in: PubMed
    Score: 0.046
  155. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine. 2021 Aug; 38:100997.
    View in: PubMed
    Score: 0.046
  156. Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. J Am Coll Cardiol. 2021 02 09; 77(5):559-571.
    View in: PubMed
    Score: 0.045
  157. Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2021 05 01; 146:15-21.
    View in: PubMed
    Score: 0.045
  158. Ten things to know about ten cardiovascular disease risk factors. Am J Prev Cardiol. 2021 Mar; 5:100149.
    View in: PubMed
    Score: 0.045
  159. Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events: The ARIC Carotid Magnetic Resonance Imaging Study. JAMA Cardiol. 2021 01 01; 6(1):79-86.
    View in: PubMed
    Score: 0.045
  160. Cardiovascular risk and complications associated with COVID-19. Am J Cardiovasc Dis. 2020; 10(4):479-489.
    View in: PubMed
    Score: 0.044
  161. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. J Am Coll Cardiol. 2020 08 18; 76(7):781-793.
    View in: PubMed
    Score: 0.043
  162. Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity: A Pooled Cohort Analysis. Circulation. 2020 08 18; 142(7):657-669.
    View in: PubMed
    Score: 0.043
  163. Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. JACC Case Rep. 2020 Jun 17; 2(7):1042-1045.
    View in: PubMed
    Score: 0.043
  164. Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction. Am J Med. 2020 11; 133(11):1293-1301.e1.
    View in: PubMed
    Score: 0.043
  165. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. J Am Coll Cardiol. 2019 10 15; 74(15):1926-1942.
    View in: PubMed
    Score: 0.041
  166. High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. J Am Geriatr Soc. 2019 11; 67(11):2353-2361.
    View in: PubMed
    Score: 0.040
  167. ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
    View in: PubMed
    Score: 0.040
  168. Understanding by General Providers of the Echocardiogram Report. Am J Cardiol. 2019 07 15; 124(2):296-302.
    View in: PubMed
    Score: 0.040
  169. Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circ Genom Precis Med. 2019 04; 12(4):e002470.
    View in: PubMed
    Score: 0.039
  170. Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circ Genom Precis Med. 2019 04; 12(4):e002471.
    View in: PubMed
    Score: 0.039
  171. Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Atherosclerosis. 2019 03; 282:52-56.
    View in: PubMed
    Score: 0.039
  172. Are All Benefits and Harms Equal? J Am Coll Cardiol. 2018 08 14; 72(7):819-820.
    View in: PubMed
    Score: 0.038
  173. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018 07 10; 72(2):156-169.
    View in: PubMed
    Score: 0.038
  174. Correction to: Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions. Curr Atheroscler Rep. 2018 06 19; 20(9):42.
    View in: PubMed
    Score: 0.037
  175. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. J Am Heart Assoc. 2018 06 09; 7(12).
    View in: PubMed
    Score: 0.037
  176. Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. J Clin Lipidol. 2018 Sep - Oct; 12(5):1141-1145.
    View in: PubMed
    Score: 0.037
  177. Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions. Curr Atheroscler Rep. 2018 05 21; 20(7):35.
    View in: PubMed
    Score: 0.037
  178. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol. 2017 07; 5(7):534-543.
    View in: PubMed
    Score: 0.035
  179. A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience. J Clin Lipidol. 2017 May - Jun; 11(3):596-599.
    View in: PubMed
    Score: 0.034
  180. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. Int J Cardiol. 2017 Apr 15; 233:61-66.
    View in: PubMed
    Score: 0.034
  181. Myocardial Injury, Obesity, and the Obesity Paradox: The ARIC Study. JACC Heart Fail. 2017 01; 5(1):56-63.
    View in: PubMed
    Score: 0.034
  182. Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis. 2016 10; 253:156-163.
    View in: PubMed
    Score: 0.033
  183. Magnetic Resonance Venous Volume Measurements in Peripheral Artery Disease (from ELIMIT). Am J Cardiol. 2016 Nov 01; 118(9):1399-1404.
    View in: PubMed
    Score: 0.033
  184. The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2016 09; 23(14):1529-36.
    View in: PubMed
    Score: 0.032
  185. Plaque Volume of Carotid Endarterectomy Specimens Measured by 3D Ultrasound Technology. JACC Cardiovasc Imaging. 2016 09; 9(9):1118-1119.
    View in: PubMed
    Score: 0.031
  186. Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults: Atherosclerosis Risk in Communities Study. Hypertension. 2015 Sep; 66(3):474-80.
    View in: PubMed
    Score: 0.030
  187. Postprandial effects on arterial stiffness parameters in healthy young adults. Vasc Med. 2015 Dec; 20(6):501-8.
    View in: PubMed
    Score: 0.030
  188. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort. JAMA Intern Med. 2015 Jan; 175(1):138-40.
    View in: PubMed
    Score: 0.029
  189. Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol. 2014 Dec 30; 64(25):2743-9.
    View in: PubMed
    Score: 0.029
  190. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. Hypertension. 2015 Jan; 65(1):78-84.
    View in: PubMed
    Score: 0.029
  191. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014 Jun; 234(2):249-53.
    View in: PubMed
    Score: 0.028
  192. Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock. Int J Cardiol. 2014 Mar 01; 172(1):239-41.
    View in: PubMed
    Score: 0.028
  193. The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis. 2013 Dec; 231(2):371-7.
    View in: PubMed
    Score: 0.027
  194. Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. Int J Cardiol. 2013 Oct 09; 168(4):3741-6.
    View in: PubMed
    Score: 0.027
  195. Application of speckle-tracking in the evaluation of carotid artery function in subjects with hypertension and diabetes. J Am Soc Echocardiogr. 2013 Aug; 26(8):901-909.e1.
    View in: PubMed
    Score: 0.026
  196. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. Eur J Prev Cardiol. 2014 Jul; 21(7):866-75.
    View in: PubMed
    Score: 0.025
  197. A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease. J Clin Lipidol. 2013 Jan-Feb; 7(1):82-7.
    View in: PubMed
    Score: 0.025
  198. Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2012 Jan; 43(1):103-8.
    View in: PubMed
    Score: 0.024
  199. Segmental analysis of carotid arterial strain using speckle-tracking. J Am Soc Echocardiogr. 2011 Nov; 24(11):1276-1284.e5.
    View in: PubMed
    Score: 0.023
  200. Automatic quantification of muscle volumes in magnetic resonance imaging scans of the lower extremities. Magn Reson Imaging. 2011 Oct; 29(8):1065-75.
    View in: PubMed
    Score: 0.023
  201. Real-time co-registration using novel ultrasound technology: ex vivo validation and in vivo applications. J Am Soc Echocardiogr. 2011 Jul; 24(7):720-8.
    View in: PubMed
    Score: 0.023
  202. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg. 2011 Mar; 53(3):668-75.
    View in: PubMed
    Score: 0.022
  203. Efficacy and tolerability of multidrug therapy for hypertriglyceridemia. J Clin Lipidol. 2009 Oct; 3(5):341-4.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.